Skip to main content
Displaying 1 - 11 of 11
Display:
12
24
48
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy